ReviewMedical review (2021)2026
Obesity: current developments in mechanisms, diagnosis, classification and the evolution of personalized management.
Review in Medical review (2021), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efferocytosis: unifying pathogenic hub in metabolic disorders-mechanistic landscapes, targeted therapies and translational bottlenecks.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the global prevalence of overweight and obesity has exhibited a sustained upward trajectory. As an independent entity within the spectrum of chronic diseases, obesity serves as a significant pathogenic factor for multiple chronic conditions and ranks as the sixth leading risk factor for mortality and disability nationwide. It poses a severe threat to public health while imposing a considerable socioeconomic burden. The etiology of obesity is multifactorial; however, primary diagnostic modalities and therapeutic approaches remain relatively undiversified, and long-term weight maintenance remains challenging. Similar to other chronic diseases, obesity management demands a long-term multimodal strategy. This strategy must incorporate individualized treatment goals and balance the benefits and risks of different interventions to formulate personalized management plans. These plans aim to reduce body weight through multifaceted interventions, alleviate obesity-related comorbidities, enhance quality of life, and optimize overall health outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.